Jan Willem B. de Groot
About
Jan Willem B. de Groot is a scholar working on Oncology, Molecular Biology and Endocrinology, Diabetes and Metabolism.
According to data from OpenAlex, Jan Willem B. de Groot has authored 94 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Oncology, 35 papers in Molecular Biology and 16 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Jan Willem B. de Groot's work include Melanoma and MAPK Pathways (30 papers), Cancer Immunotherapy and Biomarkers (23 papers) and Cutaneous Melanoma Detection and Management (22 papers). Jan Willem B. de Groot is often cited by papers focused on Melanoma and MAPK Pathways (30 papers), Cancer Immunotherapy and Biomarkers (23 papers) and Cutaneous Melanoma Detection and Management (22 papers). Jan Willem B. de Groot collaborates with scholars based in Netherlands, United States and Germany. Jan Willem B. de Groot's co-authors include John Th. M. Plukker, Thera P. Links, Robert M.W. Hofstra, Ana Arance, Dirk Schadendorf, Gabriella Liszkay, Caroline Robert, Ivana Krajsová, Ralf Gutzmer and Mario Mandalà and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Annals of Internal Medicine.
In The Last Decade
Jan Willem B. de Groot
87 papers receiving 3.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Jan Willem B. de Groot Netherlands | 27 | 1.9k | 1.5k | 829 | 442 | 367 | 94 | 3.2k | ||
| Jean Charles Soria France | 25 | 1.2k 0.7× | 1.5k 1.0× | 469 0.6× | 154 0.3× | 965 2.6× | 48 | 3.1k | ||
| James R. Vasselli United States | 21 | 1.2k 0.6× | 1.6k 1.1× | 1.2k 1.4× | 412 0.9× | 1.2k 3.2× | 37 | 3.7k | ||
| Vandana G. Abramson United States | 34 | 2.7k 1.4× | 1.4k 0.9× | 440 0.5× | 149 0.3× | 1.3k 3.5× | 119 | 4.9k | ||
| Stephen Leong United States | 23 | 1.1k 0.6× | 842 0.6× | 210 0.3× | 85 0.2× | 471 1.3× | 73 | 2.3k | ||
| Michael Millward Australia | 25 | 1.7k 0.9× | 1.1k 0.7× | 146 0.2× | 117 0.3× | 1.1k 3.1× | 43 | 2.9k | ||
| Hiroshi Sonoo Japan | 26 | 1.3k 0.7× | 820 0.5× | 335 0.4× | 148 0.3× | 292 0.8× | 123 | 2.3k | ||
| Theodoros Foukakis Sweden | 33 | 2.1k 1.1× | 1.4k 0.9× | 421 0.5× | 122 0.3× | 726 2.0× | 135 | 4.1k | ||
| Andréa Varga France | 33 | 3.0k 1.6× | 1.2k 0.8× | 182 0.2× | 239 0.5× | 1.2k 3.4× | 107 | 4.6k | ||
| Iván Márquez‐Rodas Spain | 25 | 3.0k 1.6× | 1.3k 0.9× | 112 0.1× | 195 0.4× | 778 2.1× | 120 | 4.1k | ||
| Frauke Bentzien United States | 10 | 665 0.4× | 821 0.5× | 248 0.3× | 93 0.2× | 522 1.4× | 12 | 2.1k |
Countries citing papers authored by Jan Willem B. de Groot
Since
Specialization
Citations
This map shows the geographic impact of Jan Willem B. de Groot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Willem B. de Groot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Willem B. de Groot more than expected).
Fields of papers citing papers by Jan Willem B. de Groot
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jan Willem B. de Groot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Willem B. de Groot. The network helps show where Jan Willem B. de Groot may publish in the future.
Co-authorship network of co-authors of Jan Willem B. de Groot
This figure shows the co-authorship network connecting the top 25 collaborators of Jan Willem B. de Groot. A scholar is included among the top collaborators of Jan Willem B. de Groot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Willem B. de Groot. Jan Willem B. de Groot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bloem, Martin W., Karijn P.M. Suijkerbuijk, Franchette W.P.J. van den Berkmortel, et al.. (2025). Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry. European Journal of Cancer. 223. 115514–115514.
2.
Groot, Saskia de, Hedwig M. Blommestein, B Leeneman, et al.. (2025). Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma. Medical Decision Making. 45(3). 302–317.
3.
Galien, René, Maarten J. Deenen, Dirk Jan A. R. Moes, et al.. (2025). Precision Treatment of Patients With GI Cancer Using Pre-emptive DPYD Genotyping/Phenotyping Plus Pharmacokinetic-Guided Dosing of 5-Fluorouracil. JCO Precision Oncology. 9(9). e2500062–e2500062.
4.
Berkmortel, Franchette van den, Marye J. Boers‐Sonderen, Jan Willem B. de Groot, et al.. (2024). Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma. European Journal of Cancer. 208. 114190–114190.
5.
Schadendorf, Dirk, Caroline Robert, Ana Arance, et al.. (2024). COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma. European Journal of Cancer. 204. 114073–114073.
6.
Kimman, Merel, Rudolf Ponds, Jan Willem T. Dekker, et al.. (2024). The Assessment of Burden of ColoRectal Cancer (ABCRC)-tool; a validity and reliability study. European Journal of Surgical Oncology. 50(4). 108032–108032.
7.
Zeijl, Michiel C.T. van, Liesbeth C. de Wreede, Michel W.J.M. Wouters, et al.. (2023). Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands. Journal of Immunotherapy. 46(5). 197–204.
8.
Ascierto, Paolo A., Reinhard Dummer, Helen Gogas, et al.. (2023). Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial. Journal of Clinical Oncology. 41(29). 4621–4631.
9.
Maring, Jan Gerard, et al.. (2023). Role of Patient-Reported Outcomes in Clinical Trials in Metastatic Colorectal Cancer: A Scoping Review. Cancers. 15(4). 1135–1135.
10.
Geurts, Birgit S., Laurien J. Zeverijn, Gijs F. de Wit, et al.. (2023). Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol. The Oncologist. 29(5). 431–440.
11.
Baarslag, Manuel A., Joosje H. Heimovaara, Jessica S.W. Borgers, et al.. (2023). Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab. New England Journal of Medicine. 389(19). 1790–1796.
12.
Wouters, Michel W.J.M., Doranne L. Hilarius, Liesbeth C. de Wreede, et al.. (2022). End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study. JCO Oncology Practice. 18(10). e1611–e1620.
13.
Eertwegh, Alfonsus Johannes Maria van den, Liesbeth C. de Wreede, Doranne L. Hilarius, et al.. (2021). Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands. Cancers. 13(20). 5077–5077.
14.
Homs, Marjolein Y.V., Thierry van den Bosch, Koop Bosscha, et al.. (2021). Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study. International Journal of Molecular Sciences. 22(20). 10902–10902.
15.
Tolmeijer, Sofie H., Rutger H.T. Koornstra, Jan Willem B. de Groot, et al.. (2021). Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma. Cancers. 13(15). 3913–3913.
16.
Leeneman, B, Carin A. Uyl‐de Groot, Maureen J.B. Aarts, et al.. (2020). Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs. Cancers. 12(4). 1003–1003.
17.
Kooij, Monique K. van der, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, et al.. (2020). Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response. Cancers. 12(8). 2072–2072.
18.
Groot, Jan Willem B. de, Helle‐Brit Fiebrich, Jacques C. de Graaf, et al.. (2020). Feasibility of volatile organic compound in breath analysis in the follow-up of colorectal cancer: A pilot study. European Journal of Surgical Oncology. 46(11). 2068–2073.
19.
Meulendijks, Didier, Jan Willem B. de Groot, Maartje Los, et al.. (2016). Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first‐line treatment of patients with advanced HER2‐negative gastric cancer: A multicenter phase 2 study. Cancer. 122(9). 1434–1443.
20.
Groot, Jan Willem B. de, Frans Peters, & Anna K.L. Reyners. (2010). Behandeling van obstipatie in de palliatieve fase. Nederlandsch tijdschrift voor geneeskunde/Nederlands tijdschrift voor geneeskunde/NTvG-databank. 154(49).
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jean Charles Soria Breakdown of academic impact, for papers by James R. Vasselli Breakdown of academic impact, for papers by Vandana G. Abramson Breakdown of academic impact, for papers by Stephen Leong Breakdown of academic impact, for papers by Michael Millward Breakdown of academic impact, for papers by Hiroshi Sonoo Breakdown of academic impact, for papers by Theodoros Foukakis Breakdown of academic impact, for papers by Andréa Varga Breakdown of academic impact, for papers by Iván Márquez‐Rodas Breakdown of academic impact, for papers by Frauke Bentzien